Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Sponsor
University Health Network, Toronto
Study ID
NCT00121277
Phase
PHASE1
Status
Completed

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as vorinostat and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat and capecitabine in treating patients with unresectable or metastatic solid tumors.

Key Dates

Start date
Sep 30, 2005
Status verified
Jul 2015
Primary completion
Aug 31, 2009

Study Design

Enrollment
28 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SAHA (Suberoylanilide Acid) with Capecitabine

Primary Outcome Measure

Maximum tolerated doses of vorinostat (SAHA) and capecitabine [ Time Frame: 1 cycle ]

Related Studies